Drugs That Induce Repolarization Abnormalities Cause Bradycardia in Zebrafish

Background—Drug-induced QT prolongation and torsades de pointes remain significant and often unpredictable clinical problems. Current in vitro preclinical assays are limited by biological simplicity, and in vivo models suffer from expense and low throughput. Methods and Results—During a screen for the effects of 100 small molecules on the heart rate of the zebrafish, Danio rerio, we found that drugs that cause QT prolongation in humans consistently caused bradycardia and AV block in the zebrafish. Of 23 such drugs tested, 18 were positive in this initial screen. Poor absorption explained 4 of 5 false-negative results, as demonstrated by microinjection. Overall, 22 of 23 compounds that cause repolarization abnormalities were positive in this assay. Antisense “knockdown” of the zebrafish KCNH2 ortholog yielded bradycardia in a dose dependent manner confirming the effects of reduction of repolarizing potassium current in this model. Classical drug-drug interactions between erythromycin and cisapride, as well as cimetidine and terfenadine, were also reproduced. Conclusion—This simple high-throughput assay is a promising addition to the repertoire of preclinical tests for drug-induced repolarization abnormalities. The genetic tractability of the zebrafish will allow the exploration of heritable modifiers of such drug effects.

[1]  D. Roden Acquired Long QT Syndromes and the Risk of Proarrhythmia , 2000, Journal of cardiovascular electrophysiology.

[2]  F. Cappuccio,et al.  Variant of SCN5A Sodium Channel Implicated in Risk of Cardiac Arrhythmia , 2002, Science.

[3]  M. Fishman,et al.  "Physiological genomics": mutant screens in zebrafish. , 1998, American journal of physiology. Heart and circulatory physiology.

[4]  D. Roden,et al.  Drug Block of I Kr : Model Systems and Relevance to Human Arrhythmias , 2001, Journal of cardiovascular pharmacology.

[5]  J. Fish,et al.  Electrical heterogeneity within the ventricular wall , 2001, Basic Research in Cardiology.

[6]  S. Ekker,et al.  Effective targeted gene ‘knockdown’ in zebrafish , 2000, Nature Genetics.

[7]  P. C. Viswanathan,et al.  Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes , 2002, Circulation.

[8]  M. Sanguinetti,et al.  Molecular and Cellular Mechanisms of Cardiac Arrhythmias , 2001, Cell.

[9]  D. Roden Pharmacogenetics and drug-induced arrhythmias. , 2001, Cardiovascular research.

[10]  C Antzelevitch,et al.  Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. , 1996, Journal of the American College of Cardiology.

[11]  A. Camm,et al.  Congenital and acquired long QT syndrome. , 2000, European heart journal.

[12]  A. V. van Ginneken,et al.  Effects of delayed rectifier current blockade by E-4031 on impulse generation in single sinoatrial nodal myocytes of the rabbit. , 1995, Circulation research.

[13]  D M Roden,et al.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Rosen,et al.  Sex, hormones, and repolarization. , 2002, Cardiovascular research.

[15]  G. Breithardt,et al.  Experimental models of torsade de pointes. , 1998, Cardiovascular research.

[16]  D. Roden,et al.  The genetic basis of variability in drug responses , 2002, Nature Reviews Drug Discovery.

[17]  Hua-rong Lu,et al.  In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity , 2002, Fundamental & clinical pharmacology.

[18]  M. Fishman,et al.  Defective "pacemaker" current (Ih) in a zebrafish mutant with a slow heart rate. , 1997, Proceedings of the National Academy of Sciences of the United States of America.